Brief: CF Pharmtech Announces Approval Of Clinical Trial Application For Olopatadine Hydrochloride, Mometasone Furoate Monohydrate Nasal Spray
09/03/2026 01:32
March 9 (Reuters) - CF PharmTech Inc 2652.HK: APPROVAL OF CLINICAL TRIAL APPLICATION FOR OLOPATADINE HYDROCHLORIDE, MOMETASONE FUROATE MONOHYDRATE NASAL SPRAY BY NMPA Further company coverage: 2652.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CF PharmTech
See all newsBrief: CF Pharmtech Receives NMPA Implied Clinical Trial Approvals For ICF001 In IPF And PPF
Brief: CF Pharmtech To Place 21.7 MLN New H Shares At HK$13.82 Per Share
Brief: CF Pharmtech Says Nmpa Approves Ind Application For ICF004 As Class 1 New Drug
Brief: CF Pharmtech Inc To Nominate Zhang Jingjing As Candidate For Executive Director
CF PharmTech climbs most in 4 weeks on product marketing application in Asia